Document Type : Systematic review


1 Department of Anesthesiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Eye Research Center, Department of Ophthalmology, Mashhad University of Medical Science, Mashhad, Iran.


Introduction: Oxygen therapy used for preterm infant disease might be associated with oxygen toxicity or oxidative stress. The exact oxygen concentration to control and maintain the arterial oxygen saturation balance is not certainly clear. We aimed to compare the efficacy of higher or lower oxygen saturations on the development of severe retinopathy of prematurity which is a major cause of blindness in preterm neonates.
Methods: PubMed was searched for obtaining the relevant articles. A total of seven articles were included after studying the titles, abstracts, and the full text of retrieved articles at initial search. Inclusion criteria were all the English language human clinical randomized controlled trials with no time limitation, which studied the efficacy of low versus high oxygen saturation measured by pulse oximetry in preterm infants.
Result: It can be suggested that lower limits of oxygen saturations have higher efficacy at postmesetural age of ≤28 weeks in preterm neonates. This relation has been demonstrated in five large clinical trials including three Boost trials, COT, and Support.
Discussion: Applying higher concentrations of oxygen supplementations at mesentural age ≥32 weeks reduced the development of retinopathy of prematurity. Lower concentrations of oxygen saturation decreased the incidence and the development of retinopathy of prematurity in preterm neonates while applied soon after the birth.
Conclusions: Targeting levels of oxygen saturation in the low or high range should be performed cautiously with attention to the postmesentural age in preterm infants at the time of starting the procedures.


Retinopathy of prematurity (ROP) or (retrolental fibroplasia (RLF) mostly occurs in premature infants as a result of abnormal vessel development in the retina of the eye, subsequent detachment from the back of the eye, and leading to blindness (1).
ROP, a major developmental disorder, threatens the quality of life in premature infants.
ROP has been reported as the second major cause of blindness in premature infants in USA.
Based on pathological evidence, this condition has been made of two distinct phases including hyperoxia and cessation of normal retinal blood vessel growth (phase 1), and hypoxia and pathological neovascularization (2).
The presence of ROP could be estimated through routine ophthalmic examinations at two-week intervals after the oxygen therapy until the resolution of retinopathy and the assessment of the grading based on the International Classification of Retinopathy of Prematurity (3).
This vasoproliferative disease was firstly discovered by Terry in 1942 and it has been proposed as a common cause of blindness in premature infants until now.
Application of oxygen administration during neonatal treatment procedures is a complex and critical field of perinatal medicine with various discrepancies (4,5). Although oxygen administration might be vital during therapeutic strategies in preterm neonates, some adverse effects might be associated with these procedures such as ROP, adverse neurodevelopmental outcomes such as hearing loss, bronchopulmonary dysplasia, and necrotizing enterocolitis (6).
Administration of excessive oxygen in premature infants has been proposed as a major risk factor contributing with the progression of ROP for more than 50 years ago (7,8). The appropriate oxygen-saturation level in preterm infants is an important issue which is still under investigation. Several studies have been performed to address the association between reduced oxygen-saturation at early weeks after birth and reduction of severe ROP in preterm neonates (9-11). These studies showed that a simple change in oxygen saturation limits could reduce the occurrence of prethreshold ROP in preterm infants. They also proposed that the exposure of preterm neonates to hyperoxia could negatively affect the retinal vascular endothelial growth factor (VEGF) and damage normal retinal vascular migration which leads to vaso-obliteration. Thus, it is proposed that exposure to SpO2 (arterial oxygen saturation) values between 83% and 93%, avoids the vaso-obliterative phase and the following expansion of severe ROP (11,12).  In contrast, based on different protocols, application of higher oxygen saturation at later postmenstrual ages is proposed to be effective in reducing the progression and occurrence of ROP (13,14).
In this systematic review, we aim to compare the efficacy of higher or lower oxygen saturations on the development of severe retinopathy of prematurity which is a major cause of blindness in preterm neonates.

Relevant articles were retrieved through a comprehensive literature search in PubMed. All English language articles were identified with no time limitation based on the following search terms: “retinopathy of prematurity and oxygen therapy”. All the human randomized controlled clinical trials (RCTs) published in English studied the efficacy of supplemental low and high SpO2 in premature infants, measured by pulse oximetry were eligible to be included. The incidence of ROP at different stag es was also regarded as the outcome in all the included studies. Exclusion criteria were all the case reports, reviews, and the studies with no certain oxygen saturation level.

Study selection
Abstract and title of the articles obtained at primary search were studied. The results of those that discussed the effect of oxygen on the incidence of ROP were extracted. Reference lists of the retrieved articles were also studied to prevent the possibility of missing any relevant article.

Data extraction
Based on the retrieved studies, the effect of low oxygen saturation (70% - 96%) versus high oxygen saturation (85% - 100%), at any time before the hospital discharge of extremely premature infants born at a gestational age of ≤ 30 weeks was estimated. Quality assessment of the included studies is detailed in Table 1.

At the initial search, 788 articles were obtained from which 768 articles were excluded based on the exclusion criteria by screening the title and abstracts. Therefore, 20 articles were selected for further evaluation of the full text. Overall, five articles that were the most relevant studies were included. Included studies were published between 1999 and 2013.A total of 5918 infants were evaluated in included studies, 2959 infants were in groups treated with low oxygen supplementation and the same number in groups with high oxygen saturation. The mean gestational age was almost 26 weeks. Two RCTs compared the efficacy of lower oxygen (<%96-89%) and higher oxygen (<99%-94%) levels at postmenstrual ages of ≥32 weeks with a total number of 1007 infants, while in other studies, low oxygen saturation (96%-70%) versus high oxygen saturation (89%-85%) were studied (15,16).

In this review, we aimed to study the incidence rate and progression of severe ROP in premature infants under the oxygen-saturation procedure measured by pulse oximetry.  
The advantages of  low and high oxygen saturation on severe ROP depend on the pathological phases of the disease. It has been proposed that the first phase of the ROP consists of hyperoxia and following by vaso-obliterative phase during 30 to 32 weeks of postmesentural age; supplemental oxygen could arrest VEGF, interrupt normal vessel growth, and deteriorate the existing vessels. During the second phase of the disease (after the 32 weeks of gestation), the presence of hypoxia increases VEGF expression and the subsequent pathologic neovascularization. Therefore, administration of appropriate level of therapeutic oxygen-saturation at each phase of the disease could adjust VEGF expression and pathologic neovascularization due to the ROP. In this regard, there is a positive relation between postmenstrual age and the development of ROP.
Previous laboratory and experimental examinations have proven the contribution of elevated VEGF in pathological retinal vasculature of animal models, transgenic mouse models, and nonhuman primates (20-22).
Although the appropriate level of oxygen saturation is not clearly revealed, pulse oximetry is nowadays routinely used for the monitoring of oxygen-fluctuation in preterm infants.
In accordance with the mentioned subjects, it could be suggested that lower limits of oxygen saturations have higher efficacy at postmesetural age of ≤28 weeks in preterm neonates. This relation has been demonstrated in 5 large clinical trials including three Boost trials, COT, and Support study groups (17-19).
Based on the study of Askie et al., in 2003, applying a higher oxygen-saturation range after the postmesetural of 32 weeks in a subgroup of extremely preterm infants, requirement for ophthalmic intervention might decrease the due to severe eye disease (15).
Nevertheless, this trial did not have appropriate statistical strength to reveal the significant differences in secondary eye-related outcomes by applying higher levels of oxygen saturation, and further large trials are suggested to confirm the efficacy of different oxygen saturation ranges on the incidence rate of ROP. Similar result was also reported in another study performed in 2000, which suggested a no significant decreased risk of ROP progression following higher oxygen-saturation levels applied at almost 2.5±35.4 weeks of postmesentural age (16).
Some limitations were associated with the study of STOP-ROP multicenter group, including the application of high saturation oxygen at a mean of 2.5± 35.4 weeks of age. Because of the possibility of the enrolled infants to be at phase 1 or 2 of the ROP (posmesentural age ranged from 30 to 48 weeks), the protective effect of oxygen-saturation therapy could not be determined exactly. According to the STOP-ROP study, high-oxygen administration might be started too early in patients at phase 1 of the ROP and too late in patients at phase 2 of the disease (16).
Although the optimum oxygen level for the treatment of ROP in preterm infants remained uncertain, the high level of oxygen-saturation chosen in the STOP-ROP trial and the one performed by Askie et al., might be another contributing factor that reduced the strength of the treatment efficacy on neonates; 96% to 99% of oxygen level, versus ≥98% in other surveys (14, 16).
Therefore, it seems that higher oxygen levels (≥98%) could result in more protective effect regarding the regression of prethreshold ROP.
In contract with the two mentioned studies, results obtained through three large clinical randomized trials (COT, three BOOST studies, and Support) showed that application of high oxygen saturation compared with low concentration, within the initial time after the birth could increase the mortality rate and also develop severe ROP (17-19).
In all these five trials, supplemental oxygen saturation was applied soon after birth, and they confirmed that lower target ranges of oxygenation reduced the incidence of severe retinopathy.
Strategies of targeting levels of oxygen saturation in low or high range should be performed cautiously and careful attention should be devoted to the postmesentural age at the time of starting the procedures in preterm infants.

Based on included articles, it can be suggested that both the concentration of the applied oxygen and the timing of the oxygen application are important factors in severe ROP risk reduction. According to the results, higher oxygen saturation levels (≥94%-99%) reveal higher advantages in ROP risk reduction, at ≥36 weeks of postmesentural age.
We would like to thank Clinical Research Development Unit of Ghaem Hospital for their assistant in this manuscript.

Conflict of Interest
The authors declare no conflict of interest.

  1. Shin DH, Kong M, Kim SJ, et al. Risk factors and rate of progression for zone I versus zone II type 1 retinopathy of prematurity. J AAPOS. 2014;18:124-128.
  2. Patz A, Eastham A, Higginbotham DH, et al. Oxygen studies in retrolental fibroplasia. II. The production of the microscopic changes of retrolental fibroplasia in experimental animals. Am J Ophthalmol. 1953;36:1511-1522.
  3. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991-999.
  4. Higgins RD, Bancalari E, Willinger M, et al. Executive summary of the workshop on oxygen in neonatal therapies: controversies and opportunities for research. Pediatrics. 2007;119:790-796.
  5. Tin W. Oxygen therapy: 50 years of uncertainty. Pediatrics. 2002;110:615-616.
  6. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-1729.
  7. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38:397-432.
  8. Ashton N, Ward B, Serpell G. Role of oxygen in the genesis of retrolental fibroplasia; a preliminary report. Br J Ophthalmol. 1953;37:513-520.
  9. Tin W, Milligan D, Pennefather P, et al. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001;84:F106-F110.
  10. Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS. 2006;10:445-448.
  11. Wright KW, Sami D, Thompson L, et al. A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. Trans Am Ophthalmol Soc. 2006;104:78-84.
  12. Wallace DK, Veness-Meehan KA, Miller WC. Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels. J AAPOS. 2007;11:170-174.
  13. McGregor ML, Bremer DL, Cole C, et al. Retinopathy of prematurity outcome in infants with prethreshold retinopathy of prematurity and oxygen saturation >94% in room air: the high oxygen percentage in retinopathy of prematurity study. Pediatrics. 2002;110:540-544.
  14. Gaynon MW1, Stevenson DK, Sunshine P, et al. Landers MB. Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity. J Perinatol. 1997;17:434-438.
  15. Askie LM, Henderson-Smart DJ, Irwig L, et al. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959-967.
  16. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105:295-310.
  17. Carlo WA, Finer NN, Walsh MC, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med.  2010;362:1959-1969.
  18. Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med.  2013;368:2094-20104.
  19. Schmidt B, Whyte RK, Asztalos EV, et al. Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA. 2013;309:2111-2120.
  20. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
  21. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
  22. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281-291.